Nonmalignant comorbid medical conditions, such as heart failure and emphysema, may complicate cancer treatment.
Methods:
Guidelines from the National Hospice Organization for cancer and selected nonmalignant diseases are outlined, and treatment principles for end-stage heart failure and emphysema are reviewed.
Results:
Estimates by clinicians of survivability in advanced cancer and nonmalignant disease are important in order to allow patients and family members to begin realistic advance planning. As disease progresses through its end stages to death, optimal management may include both disease-modifying and symptom-relieving interventions.
Conclusions:
A well-managed end of life is an important therapeutic option in informed consent discussions with seriously ill patients and their families.
References
1.
KnausW.A., WagnerD.P., DraperE.A.. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults.Chest.1991; 100: 1619–1636.
2.
LynnJ., TenoJ.M., HarrellFEJr. Accurate prognostications of death: opportunities and challenges for clinicians.West J Med.1995; 163: 250–257.
3.
A controlled trial to improve care for seriously ill hospitalized patients. The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT). The SUPPORT Principal Investigators.JAMA.1995; 274: 1591–1598.
4.
ThibaultG.. Prognosis and clinical predictive models for critically ill patients. In: FieldM.J., CasselC.K., eds. Approaching Death: Improving Care at the End of Life.Committee on Care at the End of Life, Division of Health Care Services, Institute of Medicine. Washington, DC: National Academy Press;1997: 358–362.
5.
BoultC., BoultL., PacalaJ.T.. Systems of care for older populations of the future.J Am Geriatr Soc.1998; 46: 499–505.
6.
National Hospice Organization Standards and Accreditation Committee, Medical Guidelines Task Force.Medical Guidelines for Determining Prognosis in Selected Cancer Diseases.1999. In press.
7.
National Hospice Organization Standards and Accreditation Committee, Medical Guidelines Task Force.Medical Guidelines for Determining Prognosis in Selected Non-Cancer Diseases.2nd ed.Arlington, Va: National Hospice Organization;1996.
8.
WeeksJ.C., CookE.F., O'DayS.J.. Relationship between cancer patients’ predictions of prognosis and their treatment preferences.JAMA.1998; 279: 1709–1714.
9.
MurdenR.A., AinslieN.K.. Recent weight loss is related to short-term mortality in nursing homes.J Gen Intern Med.1994; 9: 648–650.
10.
ChatterjeeK.. Heart failure therapy in evolution.Circulation.1996; 94: 2689–2693.
11.
CohnJ.N., ArchibaldD.G., ZiescheS.. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study.N Engl J Med.1986; 314: 1547–1552.
12.
JohnsonG., CarsonP., FrancisG.S.. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II).Circulation.1993; 87(suppl): VI32–39.
13.
LevineT.B., FranciosaJ.A., VrobelT.. Hyponatraemia as a marker for high renin heart failure.Br Heart J.1982; 47: 161–166.
14.
VisserF.C., VisserC.A.. Current controversies with ACE inhibitor treatment in heart failure.Cardiology.1996; 87: 23–28.
15.
Effects of enalapril on mortality in severe congestive heart failure.Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The Consensus Trial Study Group.N Engl J Med.1987; 316: 1429–1435.
16.
BiggerJTJr, FleissJ.L., RolnitzkyL.M.. Effect of digitalis treatment on survival after acute myocardial infarction.Am J Cardiol.1985; 55: 623–630.
17.
PackerM., GheorghiadeM., YoungJ.B.. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. RADIANCE Study.N Engl J Med.1993; 329: 1–7.
18.
BristowM.R., GilbertE.M., AbrahamW.T.. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.Circulation.1996; 94: 2807–2816.
19.
PackerM., ColucciW.S., Sackner-BernsteinJ.D.. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial: Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.Circulation.1996; 94: 2793–2799.
20.
ChapmanK.R.. Therapeutic approaches to chronic obstructive pulmonary disease: an emerging consensus.Am J Med.1996; 100: 5S–10S.
21.
CallahanC.M., DittusR.S., KatzB.P.. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis.Ann Intern Med.1991; 114: 216–223.
BraunS.R., McKenzieW.N., CopelandC.. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease.Arch Intern Med.1989; 149: 544–547.
24.
GrossN.J., BankwalaZ.. Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease. Comparison with a beta-adrenergic agent.Am Rev Respir Dis.1987; 136: 1091–1094.
ChapmanK.R.. The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease.Lung.1990; 168: 295–303.
27.
PakesG.E., BrogdenR.N., HeelR.C.. Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis.Drugs.1980; 20: 237–266.
28.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma.This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986.Am Rev Respir Dis.1987; 136: 225–244.
29.
BleeckerE.R., BrittE.J.. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.Am J Med.1991; 91: 24S–27S.
30.
Guidelines for the assessment and management of chronic obstructive pulmonary disease.Canadian Thoracic Society Workshop Group.CMAJ.1992; 147: 420–428.
31.
Nocturnal Oxygen Therapy Trial Group.Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial.Ann Intern Med.1980; 93: 391–398.
